Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation.
Barquín M, Calvo V, García-García F, Nuñez B, Sánchez-Herrero E, Serna-Blasco R, Auglytė M, Carcereny E, Rodriguez-Abreu D, López Castro R, Guirado M, Camps C, Bosch-Barrera J, Massuti B, Ortega AL, Del Barco E, Gonzalez-Larriba JL, Aguiar D, García-Campelo R, Dómine M, Agraso S, Sala MA, Oramas J, Bernabé R, Blanco R, Parejo C, Cruz A, Menasalvas E, Royuela A, Romero A, Provencio M. Barquín M, et al. Among authors: del barco e. Cancer Epidemiol. 2020 Aug;67:101737. doi: 10.1016/j.canep.2020.101737. Epub 2020 May 22. Cancer Epidemiol. 2020. PMID: 32450544
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Provencio M, et al. Among authors: del barco e. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24. Lancet Oncol. 2020. PMID: 32979984 Clinical Trial.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, Aguiar D, García-Giron C, Hidalgo J, Aguado C, González JG, Esteban E, Gómez-Aldavarí L, Moran T, Juan O, Chara LE, Marti JL, Castro RL, Ortega AL, Moreno EM, Coves J, Sánchez Peña AM, Bosch-Barrera J, Gastaldo AS, Núñez NF, Del Barco E, Cobo M, Isla D, Majem M, Navarro F, Calvo V. Provencio M, et al. Among authors: del barco e. BMC Cancer. 2021 Mar 6;21(1):230. doi: 10.1186/s12885-021-07922-5. BMC Cancer. 2021. PMID: 33676426 Free PMC article.
Lung cancer patients with COVID-19 in Spain: GRAVID study.
Provencio M, Mazarico Gallego JM, Calles A, Antoñanzas M, Pangua C, Mielgo Rubio X, Nadal E, Castro RL, López-Martín A, Del Barco E, Dómine M, Franco F, Diz P, Sandoval C, Girona ES, Sullivan I, Sala MÁ, Ledo GG, Cucurull M, Mosquera J, Martínez M, Chara LE, Arriola E, Herrera BE, Jarabo JR, Álvarez RÁ, Baena J, Cao MG. Provencio M, et al. Among authors: del barco e. Lung Cancer. 2021 Jul;157:109-115. doi: 10.1016/j.lungcan.2021.05.014. Epub 2021 May 14. Lung Cancer. 2021. PMID: 34016490 Free PMC article.
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, García-Campelo R, Del Barco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, García Coves P, Domènech M, Provencio M. Franco F, et al. Among authors: del barco e. PLoS One. 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761. eCollection 2021. PLoS One. 2021. PMID: 34077442 Free PMC article.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Laza-Briviesca R, et al. Among authors: del barco e. Clin Transl Med. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. Clin Transl Med. 2021. PMID: 34323406 Free PMC article.
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquín M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Casarrubios M, et al. Among authors: del barco e. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376534 Free PMC article.
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Sierra-Rodero B, et al. Among authors: del barco e. J Immunother Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. J Immunother Cancer. 2021. PMID: 34446577 Free PMC article.
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
Gutiérrez L, Royuela A, Carcereny E, López-Castro R, Rodríguez-Abreu D, Massuti B, González-Larriba JL, García-Campelo R, Bosch-Barrera J, Guirado M, Camps C, Dómine M, Bernabé R, Casal J, Oramas J, Ortega AL, Sala MA, Padilla A, Aguiar D, Juan-Vidal O, Blanco R, Del Barco E, Martínez-Banaclocha N, Benítez G, de Vega B, Hernández A, Saigi M, Franco F, Provencio M. Gutiérrez L, et al. Among authors: del barco e. BMC Cancer. 2021 Aug 31;21(1):977. doi: 10.1186/s12885-021-08713-8. BMC Cancer. 2021. PMID: 34465283 Free PMC article.
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio M, Rodríguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, López Vivanco G, Guirado M, Benítez G, Estival A, Calvo V, Jiménez B, Arasanz H, Coves J, Majem M, Massutí B, Vázquez S, Juan-Vidal O, Collazo-Lorduy A, Gozálvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, López-Martin A, Córdoba JF, de Asís Aparisi F, Zafra M, Mosquera J, Pérez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martín P, Cuesta de Juan S, Cobo M. Provencio M, et al. Among authors: del barco e. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. doi: 10.21037/tlcr-21-504. Transl Lung Cancer Res. 2022. PMID: 35242627 Free PMC article.
74 results